Search for


TEXT SIZE

search for



Clinical Study of Non-Invasive Prenatal Testing Using Next-Generation Sequencing
J Lab Med Qual Assur 2015;37:214-218
Published online December 31, 2015
© 2015 Korean Association of Quality Assurance for Clinical Laboratory.

Dong Hee Seo1,2, Dae-Yeon Cho1, Jihun Kim1, So Young Kim2, Sung Eun Cho2, and Mijin Oh1

1LabGenomics Clinical Research Institute and 2LabGenomics Clinical Laboratories, Seongnam, Korea
Correspondence to: Dong Hee Seo
LabGenomics Clinical Research Institute, 700 Daewangpangyoro, Bundang-gu, Seongnam 13488, Korea
Tel: +82-31-628-0730 Fax: +82-31-628-0701 E-mail: seo2023@nate.com
Received July 14, 2015; Revised September 16, 2015; Accepted September 17, 2015.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Background: Serological prenatal screening tests are widely used to detect fetal chromosomal abnormalities such as Down and Edward syndromes. After determining the presence of fetal cell-free DNA in maternal blood, the non-invasive prenatal test (NIPT) coupled with next-generation sequencing has been performed in other countries, therefore, we developed a domestic NIPT technology.
Methods: The results of genomics-based NIPT performed between April and May, 2015 were analyzed. Maternal blood samples were collected in a specific Cell-Free DNA BCT tube. The samples were then massively sequenced using MiSeq and NextSeq 500 (Illumina Inc., USA) using LabGenomics laboratory-developed libraries. Chromosomal abnormalities were analyzed using a bioinfomatics algorithm.
Results: A total of 464 cases were analyzed. The samples of 12 subjects had to be collected again because of a low fetal DNA fraction in the initially obtained samples. Among the 456 cases for which fetal genome results were obtained, 436 had a low risk of trisomy, 12 had a high risk for Down syndrome, two had a high risk for Edward syndrome, and four had sex chromosomal aneuploidy, showing that the positive percentage of chromosomal abnormalities was 4.4%. All 12 cases with high risk for Down syndrome were confirmed as having trisomy 21 by amniocentesis.
Conclusions: Our laboratory-developed genomics-based NIPT showed high positive predictive value, therefore, NIPT may be replaced by our own developed method.
Keywords : Non-invasive prenatal test, Trisomy, Cell-free DNA, Fetal DNA fraction
References
  1. Hwang D. The recent trend of prenatal screening. J Genet Med 2008;5:7-14.
  2. Kim S, Kim YH, Min WK. Prenatal serum marker screening in Korea: survey results. Korean J Lab Med 2007;27:28-33.
    Pubmed CrossRef
  3. Yi DY, Jung B, Kang MS, Huh JY, Paek JY, Cha DH, et al. The evaluation of integrated test as an antenatal screening test for Down셲 syndrome in Korea. Lab Med Online 2011;1:10-8.
    CrossRef
  4. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med 2013;369:499-501.
    Pubmed CrossRef
  5. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
    CrossRef
  6. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437:376-80.
    CrossRef
  7. Yang JI. Clinical application of non-invasive prenatal testing using cell free fetal DNA. J Korean Med Assoc 2014;57:771-9.
    CrossRef
  8. Lim JH, Park SY, Ryu HM. Non-invasive prenatal diagnosis of fetal trisomy 21 using cell-free fetal DNA in maternal blood. Obstet Gynecol Sci 2013;56:58-66.
    Pubmed KoreaMed CrossRef
  9. Seo DH, Cho SE, Kwak JR. An experience of using the Harmony test for genomics-based non-invasive prenatal testing. J Lab Med Qual Assur 2015;37:44-6.
    CrossRef
  10. Lee MY, Cho DY, Won HS, Hwang AR, Jeong B, Kim J, et al. Performance of Momguard, a new non-invasive prenatal testing protocol developed in Korea. Obstet Gynecol Sci 2015;58:340-5.
    Pubmed KoreaMed CrossRef
  11. Gekas J, Langlois S, Ravitsky V, Audibert F, van den Berg DG, Haidar H, et al. Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma. Appl Clin Genet 2014;7:127-31.
    Pubmed KoreaMed CrossRef
  12. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218-24.
    Pubmed KoreaMed CrossRef
  13. Yang YH, Han SH, Lee KR. Noninvasive prenatal diagnosis using cell-free fetal DNA in maternal plasma:clinical applications. J Genet Med 2011;8:1-16.
    CrossRef
  14. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alphafetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886-94.
    CrossRef
  15. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545:Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4.
    Pubmed CrossRef
  16. Han SH, An JW, Jeong GY, Yoon HR, Lee A, Yang YH, et al. Clinical and cytogenetic findings on 31,615 mid-trimester amniocenteses. Korean J Lab Med 2008;28:378-85.
    Pubmed CrossRef
  17. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370:799-808.
    Pubmed CrossRef
  18. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9.
    Pubmed CrossRef
  19. Willems PJ, Dierickx H, Vandenakker E, Bekedam D, Segers N, Deboulle K, et al. The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands. Facts Views Vis Obgyn 2014;6:7-12.
    Pubmed KoreaMed